Ofev (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases

Boehringer Ingelheim

4 March 2021 - Ofev is the first treatment available in Canada for chronic fibrosing interstitial lung diseases with a progressive phenotype, which affects patients across more than 200 rare lung disorders.

Boehringer Ingelheim is pleased to announce positive recommendations from CADTH) and the INESSS for Ofev (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype when certain conditions are met.

Read Boehringer Ingelheim press release

Michael Wonder

Posted by:

Michael Wonder